New to The Street TV airs Anchor Jane King’s interview with Tonix Pharmaceuticals, Inc.’s (NASDAQ: TNXP) CEO, Dr. Seth Lederman, MD. Viewers get an update about Tonix Pharmaceuticals, Inc.’s Covid-19 vaccine, antiviral pharmaceutical, and “Long” Covid-19 novel treatments and products. Currently, in the market, there are three (3) types of treatments in the fight against Covid-19: mRNA vaccines, antiviral therapies, and monoclonal antibodies. Seth gives a comparison and talks about the limitations of each available Covid-19 treatment. TNXP’s live vaccine, TNX-1800, in development, offers long-term protection beyond the currently used mRNA vaccines. Another in development therapy, the Company’s TNX-3500, an oral antiviral pharmaceutical, clinically shows about 65 times more potent than remdesivir in inhibiting Covid. Test combining TNX-3500 and remdesivir shows a robust protective solution. TNX-3500 is an investigational new drug not yet approved for use. Seth talks about the Company’s upcoming clinical trials on its treatment for “Long Covid.” With its new 40,000+ sq. ft. location in Frederick, Maryland, a known biotech /biodefense sector area in the US, the facility and its personnel allow ongoing clinical trials and scientific development programs with economies of scale operational efficiencies and effectiveness. Seth sees Tonix Pharmaceutical as an innovator in the fight against Covid and other diseases.
To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv
Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet
Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/
Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/
Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet
About New to the Street: https://newtothestreet.com/
Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list